Skip to Content

Corlopam (fenoldopam) Disease Interactions

There are 5 disease interactions with Corlopam (fenoldopam):

Major

Fenoldopam (Includes Corlopam) ↔ Congestive Heart Failure

Severe Potential Hazard, High plausibility

Applies to: Congestive Heart Failure

Fenoldopam causes a dose-related fall in blood pressure that may worsen congestive heart failure. Therapy with fenoldopam should be administered cautiously in patients with heart failure. Monitoring blood pressure at regular intervals is recommended.

References

  1. Gluck Z, Jossen L, Weidmann P, Gnadinger MP, Peheim E "Cardiovascular and renal profile of acute peripheral dopamine1- receptor agonism with fenoldopam." Hypertension 10 (1987): 43-54
  2. Brogden RN, Markham A "Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies." Drugs 54 (1997): 634-50
  3. Panacek EA, Bednarczyk EM, Dunbar LM, Foulke GE, Holcslaw TL "Randomized, prospective trial of fenoldopam vs sodium nitroprusside in the treatment of acute severe hypertension. Fenoldopam Study Group." Acad Emerg Med 2 (1995): 959-65
  4. Ventura HO, Messerli FH, Frohlich ED, Kobrin I, Oigman W, Dunn FG, Carey RM "Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension." Circulation 69 (1984): 1142-5
  5. "Product Information. Corlopam (fenoldopam)." Neurex, Menlo Park, CA.
View all 5 references
Major

Fenoldopam (Includes Corlopam) ↔ Glaucoma

Severe Potential Hazard, High plausibility

Applies to: Glaucoma/Intraocular Hypertension

Fenoldopam causes a dose-dependent increase in intraocular pressure. Therapy with fenoldopam should be administered cautiously in patients with glaucoma or intraocular hypertension. Intraocular pressure may return to baseline in 2 hours following discontinuation of fenoldopam.

References

  1. "Product Information. Corlopam (fenoldopam)." Neurex, Menlo Park, CA.
  2. Everitt DE, Boike SC, Piltz-Seymour JR, VanCoevorden R, Audet P, Zariffa N, Jorkasky D "Effect of intravenous fenoldopam on intraocular pressure in ocular hypertension." J Clin Pharmacol 37 (1997): 312-20
  3. Brogden RN, Markham A "Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies." Drugs 54 (1997): 634-50
Major

Fenoldopam (Includes Corlopam) ↔ Hypokalemia

Severe Potential Hazard, High plausibility

Applies to: Hypokalemia

The use of fenoldopam is associated with hypokalemia (less than 3 mEq/L after 6 hours of infusion). Therapy with fenoldopam should be administered cautiously in patients with preexisting hypokalemia. Monitoring serum electrolytes and potassium replacement as required is recommended.

References

  1. Panacek EA, Bednarczyk EM, Dunbar LM, Foulke GE, Holcslaw TL "Randomized, prospective trial of fenoldopam vs sodium nitroprusside in the treatment of acute severe hypertension. Fenoldopam Study Group." Acad Emerg Med 2 (1995): 959-65
  2. Ruilope LM, Robles RG, Miranda B, Tovar J, Alcazar JM, Sancho J, Rodicio JL, Martinez A, Astorga A, Beck T "Renal effects of fenoldopam in refractory hypertension." J Hypertens 6 (1988): 665-9
  3. Girbes AR, Smit AJ, Meijer S, Reitsma WD "Renal and endocrine effects of fenoldopam and metoclopramide in normal man." Nephron 56 (1990): 179-85
  4. Nichols AJ, Ruffolo RR Jr, Brooks DP "The pharmacology of fenoldopam." Am J Hypertens 3 (1990): s116-9
  5. "Product Information. Corlopam (fenoldopam)." Neurex, Menlo Park, CA.
View all 5 references
Major

Fenoldopam (Includes Corlopam) ↔ Hypotension

Severe Potential Hazard, High plausibility

Applies to: Cerebral Vascular Disorder, Hypotension

Fenoldopam may cause symptomatic hypotension that may exacerbate cerebral infarction or hemorrhage. Monitoring blood pressure closely during administration is recommended.

References

  1. Munger MA, Rutherford WF, Anderson L, Hakki AI, Gonzalez FM, Bednarczyk EM, Emmanuel G, Weed SG, Panacek EA, Green JA "Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension." Crit Care Med 18 (1990): 502-4
  2. Brogden RN, Markham A "Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies." Drugs 54 (1997): 634-50
  3. "Product Information. Corlopam (fenoldopam)." Neurex, Menlo Park, CA.
  4. Panacek EA, Bednarczyk EM, Dunbar LM, Foulke GE, Holcslaw TL "Randomized, prospective trial of fenoldopam vs sodium nitroprusside in the treatment of acute severe hypertension. Fenoldopam Study Group." Acad Emerg Med 2 (1995): 959-65
  5. White WB, Radford MJ, Gonzalez FM, Weed SG, McCabe EJ, Katz AM "Selective dopamine-1 agonist therapy in severe hypertension: effects of intravenous fenoldopam." J Am Coll Cardiol 11 (1988): 1118-23
  6. Ventura HO, Messerli FH, Frohlich ED, Kobrin I, Oigman W, Dunn FG, Carey RM "Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension." Circulation 69 (1984): 1142-5
  7. Gluck Z, Jossen L, Weidmann P, Gnadinger MP, Peheim E "Cardiovascular and renal profile of acute peripheral dopamine1- receptor agonism with fenoldopam." Hypertension 10 (1987): 43-54
View all 7 references
Major

Fenoldopam (Includes Corlopam) ↔ Tachycardia

Severe Potential Hazard, Moderate plausibility

Applies to: Tachyarrhythmia

The use of fenoldopam is associated with producing dose-related compensatory tachycardia, particularly with infusion rates greater than 0.1 mcg/kg/min in adults and >0.8 mcg/kg/min in pediatric patients. Tachycardia may diminish over time, but remains substantial at higher doses. Care should be exercised when using this agent in patients at risk.

References

  1. Ventura HO, Messerli FH, Frohlich ED, Kobrin I, Oigman W, Dunn FG, Carey RM "Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension." Circulation 69 (1984): 1142-5
  2. Gluck Z, Jossen L, Weidmann P, Gnadinger MP, Peheim E "Cardiovascular and renal profile of acute peripheral dopamine1- receptor agonism with fenoldopam." Hypertension 10 (1987): 43-54
  3. "Product Information. Corlopam (fenoldopam)." Neurex, Menlo Park, CA.
  4. Panacek EA, Bednarczyk EM, Dunbar LM, Foulke GE, Holcslaw TL "Randomized, prospective trial of fenoldopam vs sodium nitroprusside in the treatment of acute severe hypertension. Fenoldopam Study Group." Acad Emerg Med 2 (1995): 959-65
  5. Holcslaw TL, Beck TR "Clinical experience with intravenous fenoldopam." Am J Hypertens 3 (1990): s120-5
  6. Brogden RN, Markham A "Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies." Drugs 54 (1997): 634-50
View all 6 references

Corlopam (fenoldopam) drug Interactions

There are 468 drug interactions with Corlopam (fenoldopam)

Corlopam (fenoldopam) alcohol/food Interactions

There is 1 alcohol/food interaction with Corlopam (fenoldopam)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide